Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03701321
Title Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors National Cancer Institute (NCI)

multiple myeloma


Bortezomib + Daratumumab + Dexamethasone

Bortezomib + Daratumumab + Dexamethasone + Venetoclax

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.